Publications by authors named "Emily Y Weng"

Claim this Profile
A
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J Moran, Emily Y Weng

Eur Respir Jยท October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis